NGS Services Market in Europe Expected to Reach USD 1,152 Million by 2020 from USD 444 Million in 2015 at a CAGR of 21% According to European NGS Services Market 2015-2020

DUBLIN, Oct. 29, 2015 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/lq3p3f/european_ngs) has announced the addition of the "European NGS Services Market by Technology, Application, End User & Disease - Forecast to 2020" report to their offering.

The prominent players in the European NGS services market include Beijing Genomics Institute (BGI) (China), Macrogen (South Korea), Eurofins Genomics (Germany), Illumina (U.S.), DNA Vision (Belgium), CeGaT GmbH (Germany), Febit (U.S.), Genomnia (Italy), Microsynth (Switzerland), and Source Bioscience (U.K.).

The European NGS services market is primarily driven by factors such as faster and cost-efficient sequencing; rising preference of NGS over other platforms; rising prevalence of inherited diseases; application of genomics in drug discovery; growing prevalence of cancer and other malignant diseases; and partnerships among companies, R&D centers, and universities. On the other hand, factors such as lack of analytics, high dependence on grants for R&D, and stringent reimbursement policies are likely to restrict the growth of this market to a certain extent.

The European NGS services market is segmented on the basis of technology, application, end user, disease type, and country.

On the basis of technology, the European NGS services market is segmented into sequencing by synthesis (SBS), ion semiconductor, sequencing by ligation (SBL), pyro-sequencing, and SMRT. On the basis of application (I), the market is segmented into whole-genome sequencing, exome sequencing, targeted sequencing/gene panels, de novo sequencing, RNA-seq, ChiP-seq, and methyl-seq. On the basis of application (II), the market is segmented into research and clinical applications. On the basis of disease type, the market is segmented into oncology, inherited rare diseases, prenatal/neonatal disorder, and other diseases. The NGS oncology services market is further subsegmented into lung cancer, breast cancer, prostate cancer, colorectal cancer, and others. On the basis of end users, the market is segmented into research centers and academic & government institutes, hospitals and clinics, pharmaceutical and biotechnology companies, and other end users.

Regionally, the European NGS services market is segmented into the U.K., Germany, France, Italy, Spain, Netherlands, and Rest of Europe (RoE). Increasing healthcare expenditure and growth in NGS technologies are the major growth drivers in most of the regional segments.

Key Topics Covered:

1 Introduction

2 Research Methodology

3 Executive Summary

4 Market Overview

5 Industry Insights

6 Regulation and Certification Landscape

7 Customer Perception Analysis

8 Benchmark Parameters and Futuristic Trends

9 European NGS Services Market, By Technology

10 European NGS Services Market, By Application

11 European NGS Services Market, By Disease Type

12 European NGS Services Market, By End User

13 European NGS Services Market, By Geography

14 Competitive Landscape

15 Company Profiles

- Beijing Genomics Institute (BGI)

- Cegat (Centre for Genomics and Transcriptomics) GmbH

- DNA Vision SA

- Eurofins Genomics Inc.

- Febit / Comprehensive Biomarker Center GmbH (CBC)

- Genomnia Srl

- Illumina Inc.

- Macrogen Inc.

- Microsynth AG

- Seqomics

- Source Bio Science

For more information visit

http://www.researchandmarkets.com/research/lq3p3f/european_ngs

Media Contact:

Laura Wood, +353-1-481-1716, press@researchandmarkets.net

Related Links

http://www.researchandmarkets.com

SOURCE Research and Markets